title: [Clinical evaluation of ceftizoxime intravenous administration in severe infections associated with hematologic disorders. Niigata Infection Study Group].
abstract: Seventy-one patients with severe infections associated with hematologic disorders including leukemia, lymphoma and aplastic anemia were treated with ceftizoxime (CZX) in daily doses of 4-6 g for an average of 20.1 days. Infections associated with hematologic disorders consisted of sepsis and pneumonia, and most of the causative organisms appeared to be Gram-negative bacteria. Of the 64 patients who completed the trial, excellent response was observed in 16 and moderate response in 26. The rate of clinical effectiveness was 65.6%. Side effects observed during the treatment included skin rash in only 1 patient, and hepatic disorders in 6 patients. However, the relationship between CZX and these abnormal findings was not established. These results indicate that CZX is a therapeutically effective and safe antibiotic for the treatment of severe infections associated with hematologic disorders.
authors.forename: Y
authors.initials: Y
authors.lastname: Moriyama
authors.forename: A
authors.initials: A
authors.lastname: Shibata
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Iizumi
authors.forename: T
authors.initials: T
authors.lastname: Watabe
authors.forename: M
authors.initials: M
authors.lastname: Sato
authors.forename: I
authors.initials: I
authors.lastname: Kurokawa
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Sanada
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000150:complications; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015296:Ceftizoxime; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged
chemical_list: D015296:Ceftizoxime; D002439:Cefotaxime